BUZZ-Tivic Health Systems soars after meetings with White House, FDA
Shares of Tivic Health Systems surged 232.6% to $11.82 in premarket trading following positive meetings with the White House and FDA regarding military applications for its products. The discussions included potential expedited pathways and export support for its lead drug, entolimod, currently in late-stage trials for treating acute radiation syndrome. Despite this rise, TIVC shares had previously fallen 40.5% year-to-date.
Shares of medical device maker Tivic Health Systems (TIVC.O) rise 232.6% to $11.82 premarket
TIVC says it provided briefings at the White House and FDA which secured positive interest in potential military and defense applications for its biologic and bioelectronic product candidates
Both meetings were held last week in Washington D.C. - TIVC
Separately, co says it discussed the potential for expedited pathways and support for export opportunities for its lead experimental immunotherapy drug called entolimod
Entolimod is being tested in a late-stage study in patients to treat acute radiation syndrome (ARS), a condition caused by exposure to high doses of ionizing radiation
As of last close, TIVC had fallen 40.5% YTD
